This is a quick walk around of a mobile 32-slice computed tomography (CT) scanner used for surgery, brachytherapy and ...
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.
Healthcare data breaches are currently being reported at a rate of more than one a day, according to a new report from the nonprofit Institute for Healthcare IT (IHIT). And for those who think it can’t happen to them, the odds are not in their favor. Breaches reported between 2009 and 2018 have resulted in the theft or exposure of almost 190 million healthcare records, a number equal to 59 percent of the U.S. population, according to the HIPAA Journal.
Fujifilm’s APERTO Lucent is a 0.4T mid-field, open MRI system addressing today’s capability and image quality needs ...
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent early in their pregnancy, likely before many of them are aware that they are pregnant, according to a study published in the journal Radiology. The results support adherence to effective pregnancy screening measures to help reduce inadvertent exposures to these contrast agents during early pregnancy.
Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
August 19, 2019 — ViewRay Inc. announced the acceptance of publication by the International Journal of Radiation ...
SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a new approach to treating recurrent brain tumors. GammaTile Therapy is a U.S. Food and Drug Administration (FDA)-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with all types of recurrent brain tumors. The first patient was treated by John Wanebo, M.D., a neurosurgeon and an independent member of the HonorHealth medical staff.
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution for breast cancer, Lunit Insight MMG. The announcement marks the second approval of its AI solution by Korea MFDS since 2018, when Lunit had gained initial regulatory clearance of its AI software.
An international team of researchers developed a new magnetic resonance imaging (MRI) technique that can capture an image of a brain thinking by measuring changes in tissue stiffness. The results show that brain function can be tracked on a time scale of 100 milliseconds – 60 times faster than previous methods. The technique could shed new light on altered neuronal activity in brain diseases.
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
Every second counts for stroke patients, as studies show they can lose up to 27 million brain cells per minute. Researchers at The University of Texas Health Science Center at Houston (UTHealth) recently published new findings in Stroke that show patients transported to the hospital by mobile stroke unit (MSU) instead of standard ambulance received a clot-busting procedure an average of 10 minutes faster, which could potentially save up to 270 million neurons per patient.
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s signal-carrying white matter in children with the disorder, according to a study published in the journal Radiology.1 The same effects were not found in adults with ADHD.
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.
Did you know that approximately one-third of all the data in world is created by the healthcare industry and that ...
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation therapy and bone marrow transplants.
Patient portals can be a one-stop shop for patient access to health records and physicians. They can directly engage ...
SPONSORED CONTENT — EnsightTM 2.0 is the newest version of Enlitic’s data standardization software framework. Ensight is ...
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton therapy system. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.
Research on personalized medicines is gaining popularity in the cancer research industry, which has increased the need for effective and reliable diagnostic procedures and is expected to drive the growth of the whole slide imaging systems market. Growing demand for laboratory diagnosis procedures is also expected to fuel future growth, according to a new report from Persistence Market Research.
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system is now in use.
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment). The novel trial design and architecture is made possible by an international collaboration of experts in the care of patients with glioblastoma and the design of clinical trials. Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), GBM AGILE is a seamless Phase II (Efficacy and Safety)/Phase III (Confirmatory) trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer.
August 14, 2019 – Children’s veins are small and sometimes difficult to access during necessary medical treatment. When ...
August 14, 2019 — NinePoint Medical Inc. announced it has received U.S. Food and Drug Administration (FDA) clearance to ...